Page 1505 - Williams Hematology ( PDFDrive )

1480 Part X: Malignant Myeloid Diseases Chapter 89: Chronic Myelogenous Leukemia and Related Disorders 1481

414. Tsimberidou AM, Colburn DE, Welch MA, et al: Anagrelide and imatinib mesylate 441. van Deventer HW, Hall MD, Orlowski RZ, et al: Clinical course of thrombocytopenia
combination therapy in patients with chronic myeloproliferative disorders. Cancer in patients treated with imatinib mesylate for accelerated phase chronic myelogenous
Chemother Pharmacol 52:229, 2003. leukemia. Am J Hematol 71:184, 2002.
415. Cortes J, Kantarjian H: How I treat newly diagnosed chronic phase CML. Blood 120: 442. Sneed TB, Kantarjian HM, Talpaz M, et al: The significance of myelosuppression dur-
1390, 2012. ing therapy with imatinib mesylate in patients with chronic myelogenous leukemia in
416. Baccarani M, Saglio G, Goldman J, et al: Evolving concepts in the management of chronic phase. Cancer 100:116, 2004.
chronic myeloid leukemia. Recommendations from an expert panel of behalf of the 443. Santos FP, Alvarado Y, Kantarjian H, et al: Long-term prognostic impact of the use
European LeukemiaNet. Blood 108:1809, 2006. of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in
417. NCCN Practice Guidelines in Oncology. v.3.2014. Available at: http://www.nccn.org/ chronic phase treated with imatinib. Cancer 117:982, 2011.
professionsals/physician_gls/. 444. Lokeshwar N, Kumar L, Kumari M: Severe bone marrow aplasia following imatinib
418. Kantarjian HM, Talpaz M, O’Brien S, et al: Dose escalation of imatinib mesylate can mesylate in a patient with chronic myelogenous leukemia. Leuk Lymphoma 46:781,
overcome resistance to standard-dose therapy in patients with chronic myelogenous 2005.
leukemia. Blood 101:473, 2003. 445. Hensley ML, Ford JM: Imatinib treatment: Specific issues related to safety, fertility,
419. Marin D, Goldman JM, Olavarria E, Apperley JF: Transient benefit only from increas- and pregnancy. Semin Hematol 40:21, 2003.
ing the imatinib dose in CML patients who do not achieve complete cytogenetic 446. Ferrero D, Pogliani EM, Rege-Cambrin G, et al: Corticosteroids can reverse severe
remissions on conventional doses. Blood 102:2702, 2003. imatinib-induced hepatotoxicity. Haematologica 91(6 Suppl):ECR27, 2006.
420. Zonder JA, Pemberton P, Brandt H, et al: The effect of dose increase of imatinib mesy- 447. Cross TJ, Bagot C, Portmann B, et al: Imatinib mesylate as a cause of acute liver failure.
late in patients with chronic or accelerated phase chronic myelogenous leukemia with Am J Hematol 83:189, 2006.
inadequate hematologic or cytogenetic response to initial treatment. Clin Cancer Res 448. Esmaeli B, Prieto VG, Butler CE, et al: Severe periorbital edema secondary to STI571
9:2092, 2003. (Gleevec). Cancer 95:881, 2002.
421. Kantarjian H, Talpaz M, O’Brien S, et al: High-dose imatinib mesylate therapy in 449. Aduwa E, Szydlo R, Marin D, et al: Significant weight gain in patients with chronic
newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid myeloid leukemia after imatinib therapy. Blood 120:5087, 2012.
leukemia. Blood 103:2873, 2004. 450. Pappas P, Karavasilis V, Briasoulis E, et al: Pharmacokinetics of imatinib mesylate in
422. Hughes T, Branford S, White D, et al: Impact of early dose intensity on cytogenetic and end stage renal disease. A case study. Cancer Chemother Pharmacol 56:358, 2005.
molecular responses in chronic-phase CML patients receiving 600 mg/day of imatinib 451. Osorio S, Noblejas AG, Durán A, Steegmann JL: Imatinib mesylate induces hypoph-
as initial therapy. Blood 112:3967, 2008. osphatemia in patients with chronic myeloid leukemia in late chronic phase, and this
423. Cortes JE, Kantarjian HM, Goldberg SL, et al: High-dose imatinib in newly diagnosed effect is associated with response. Am J Hematol 82:394, 2007.
chronic-phase chronic myeloid leukemia: High rates of rapid cytogenetic and molec- 452. Fitter S, Dewar AL, Kostakis P, et al: Long-term imatinib therapy promotes bone for-
ular responses. J Clin Oncol 27:4754, 2009. mation in CML patients. Blood 111:2538, 2008.
424. Hehlmann R, Lauseker M, Jung-Munkwitz S, et al: Tolerability-adapted imatinib 800 453. Berman E, Nicolaides M, Maki RG, et al: Altered bone and mineral metabolism in
mg/d versus 400 mg/d versus 400 gm/d plus interferon-α in newly diagnosed chronic patients receiving imatinib mesylate. N Engl J Med 354:2006, 2006.
myeloid leukemia. J Clin Oncol 29:1634, 2011. 454. Sanchez-Gonzalez B, Pascual-Ramirez JC, Fernandez-Abellan P, et al: Severe skin
425. Castagnetti F, Palandri F, Amabile M, et al: Results of high-dose imatinib mesylate in reaction to imatinib in a case of Philadelphia-positive acute lymphoblastic leukemia.
intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: A Blood 101:2446, 2003.
phase 2 trial of the GIMEMA CML Working Party. Blood 113:4497, 2009. 455. Pascual JC, Matarredona J, Miralles J, et al: Oral and cutaneous lichenoid reaction
426. Kanda Y, Okamoto S, Tauchi T, et al: Multicenter prospective trial evaluating the tol- secondary to imatinib: Report of two cases. Int J Dermatol 45:1471, 2006.
erability of imatinib for Japanese patients with chronic myelogenous leukemia in the 456. Drummond A, Micallef-Eynaud P, Douglas WS, et al: A spectrum of skin reactions
chronic phase: Does body weight matter? Am J Hematol 83:835, 2008. caused by the tyrosine kinase inhibitor imatinib mesylate (STI 571, Glivec). Br J Hae-
427. Kobayashi S, Kimura F, Kobayashi A, et al: Efficacy of low-dose imatinib in chronic- matol 120:911, 2003.
phase chronic myelogenous leukemia patients. Ann Hematol 88:311, 2009. 457. Rule SAJ, O’Brien SG, Crossman LC: Managing cutaneous reactions to imatinib ther-
428. Deininger M, O’Brien SG, Ghilhot F, et al: International randomized study of inter- apy. Blood 100:3434, 2002.
feron vs STI571 (IRIS) 8 year follow up: Sustained survival and low risk for progres- 458. Etienne G, Cony-Makhoul P, Mahon FX: Imatinib mesylate and gray hair. N Engl J
sion or events in patients with newly diagnosed chronic myeloid leukemia in chronic Med 346:645, 2002.
phase (CML-CP) treated with imatinib. Blood 14: Abstract 1126, 2009. 459. Tjao AS, Kantarjian H, Cortes J, et al: Imatinib mesylate causes hypopigmentation in
429. de Lavallade H, Apperley JF, Khorashad JS, et al: Imatinib for newly diagnosed the skin. Cancer 98:2483, 2003.
patients with chronic myeloid leukemia: Incidence of sustained responses in an inten- 460. Beham-Schmid C, Apfelbeck U, Sill H, et al: Treatment of chronic myelogenous leu-
tion-to-treat analysis. J Clin Oncol 26:3358, 2008. kemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone
430. El-Zimaity MM, Kantarjian H, Talpaz M, et al: Results of imatinib mesylate therapy in marrow fibrosis. Blood 99:381, 2002.
chronic myelogenous leukaemia with variant Philadelphia chromosome. Br J Haema- 461. Kantarjian HM, Bueso-Ramos CE, Talpaz M, et al: The degree of bone marrow fibrosis
tol 125:187, 2004. in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate
431. Synder DS, McMahon R, Cohen SR, Slovak ML: Chronic myeloid leukemia with therapy. Leuk Lymphoma 46:993, 2005.
an e13a3 BCR-ABL fusion: Benign course responsive to imatinib with an RT-PCR 462. Buesche G, Ganser A, Schlegelberger B, et al: Marrow fibrosis and its relevance during
advisory. Am J Hematol 75:92, 2004. imatinib treatment of chronic myeloid leukemia. Leukemia 21:2420, 2007.
432. de Lemos JA, de Oliveira CM, Scerni AC, et al: Differential molecular response of the 463. Ebos JM, Tran J, Master Z, et al: Imatinib mesylate (STI-571) reduces the Bcr-Abl-
transcripts B2A2 and B3A2 to imatinib mesylate in chronic myeloid leukemia. Genet mediated vascular endothelial growth factor secretion in chronic myelogenous leuke-
Mol Res 4:803, 2005. mia. Mol Cancer Res 1:89, 2002.
433. Agirre X, Román-Gómez J, Vázquez I, et al: Coexistence of different clonal populations 464. Kvasnicka HM, Thiele J, Staib P, et al: Reversal of bone marrow angiogenesis in chronic
harboring the b3a2 (p210) and e1a2 (p190) BCR-ABL1 fusion transcripts in chronic myeloid leukemia following imatinib mesylate (STI571) therapy. Blood 103:3549,
myelogenous leukemia resistant to imatinib. Cancer Genet Cytogenet 160:22, 2005. 2004.
434. Castagnetti F, Testoni N, Luati S, et al: Deletions of the derivative chromosome 9 do 465. Chu S, McDonald T, Lin A, et al: Persistence of leukemia stem cells in chronic mye-
not influence the response and the outcome of chronic myeloid leukemia in early logenous leukemia patients in prolonged remission with imatinib treatment. Blood
chronic phase treated with inmatinib mesylate: GIMEMA CML working party analy- 118:5065, 2011.
sis. J Clin Oncol 28:2743, 2010. 466. Larson RA, Druker BJ, Guilhot F, et al: Imatinib pharmacokinetics and its correlation
435. Champagne MA, Capdeville R, Krailo M, et al: Imatinib mesylate (STI571) for treat- with response and safety in chronic-phase chronic myeloid leukemia: A subanalysis of
ment of children with Philadelphia chromosome-positive leukemia: Results from a the IRIS study. Blood 111:4022, 2008.
Children’s Oncology Group phase I study. Blood 104:2655, 2004. 467. Picard S, Titier K, Etienne G, et al: Trough imatinib plasma levels are associated with
436. Cortes J, Talpaz M, O’Brien S, et al: Effects of age on prognosis with imatinib mesylate both cytogenetic and molecular responses to standard-dose imatinib in chronic mye-
therapy for patients with Philadelphia chromosome-positive chronic myelogenous loid leukemia. Blood 109:3496, 2007.
leukemia. Cancer 98:1105, 2003. 468. Schmidli H, Peng B, Riviere GJ, et al: Population pharmacokinetics of imatinib mesy-
437. Latagliata R, Breccia M, Carmosino I, et al: Elderly patients with Ph+ chronic mye- late in patients with chronic-phase chronic myeloid leukaemia: Results of a phase III
logenous leukemia (CML): Results of imatinib mesylate treatment. Leuk Res 29:287, study. Br J Clin Pharmacol 60:35, 2005.
2005. 469. Ozdemir E, Koc Y, Kansu E: Successful treatment of chronic myeloid leukemia with
438. Guilhot F: Indications for imatinib mesylate therapy and clinical management. Oncol- imatinib mesylate in a patient with chronic renal failure on hemodialysis. Am J Hema-
ogist 9:271, 2004. tol 81:474, 2006.
439. Marin D, Marktel S, Foot N, et al: Granulocyte colony-stimulating factor reverses 470. Darkow T, Henk HJ, Thomas SK, et al: Treatment interruptions and non-adherence
cytopenia and may permit cytogenetic responses in patients with chronic myeloid with imatinib and associated healthcare costs: A retrospective analysis among man-
leukemia treated with imatinib mesylate. Haematologica 88:227, 2003. aged care patients with chronic myelogenous leukaemia. Pharmacoeconomics 25:481,
440. Quintas-Cardama A, Kantarjian H, O’Brien S, et al: Granulocyte-colony-stimulating 2007.
factor (filgrastim) may overcome imatinib-induced neutropenia in patients with 471. Shah P, Tran C, Lee FY, et al: Overriding imatinib resistance with a novel ABL kinase
chronic-phase chronic myelogenous leukemia. Cancer 100:2592, 2004. inhibitor. Science 305:399, 2004.

Kaushansky_chapter 89_p1437-1490.indd 1480 9/18/15 3:42 PM